Literature DB >> 25112420

Cardiopulmonary and anesthetic effects of the combination of butorphanol, midazolam and alfaxalone in Beagle dogs.

Jeong-Im Seo1, Suk-Hee Han, Ran Choi, Janet Han, Lyon Lee, Changbaig Hyun.   

Abstract

OBJECTIVE: To evaluate the physiological variables, arterial blood gas values, induction of anesthesia quality, and recovery quality using the combination of butorphanol, midazolam and alfaxalone in dogs. ANIMALS: Ten healthy adult Beagle dogs weighing 8.3 ± 3.1 kg.
METHODS: Rectal temperature (T), pulse rate (PR), respiratory rate (f(R)), mean arterial pressure (MAP), and arterial blood gases were measured and recorded prior to intravenous (IV) administration of butorphanol, prior to administration of both midazolam and alfaxalone IV 10 minutes later, then every 5 minutes for 20 minutes. M-mode echocardiographic left ventricular (LV) indices were measured before and 5 minutes after administration of alfaxalone. Qualitative scores for induction of anesthesia and recovery were allocated, duration of anesthesia and recovery were calculated, and adverse events were recorded.
RESULTS: Scores for induction and recovery quality were excellent. No significant adverse events were observed. Mean ± SD time from induction to extubation and to standing (full recovery) was 29 ± 6 and 36 ± 8 minutes, respectively. There were statistically significant changes in PR, f(R) and MAP after drug administration. Transient hypercarbia developed after alfaxalone injection. The echocardiographic LV indices were reduced after alfaxalone injection, although those changes were not statistically significant. CONCLUSIONS AND CLINICAL RELEVANCE: The combination of butorphanol, midazolam and alfaxalone provided excellent quality of induction of anesthesia and exerted minimal cardiopulmonary effects in healthy dogs.
© 2014 Association of Veterinary Anaesthetists and the American College of Veterinary Anesthesia and Analgesia.

Entities:  

Keywords:  alfaxalone; anesthesia; butorphanol; dog; midazolam

Mesh:

Substances:

Year:  2014        PMID: 25112420     DOI: 10.1111/vaa.12223

Source DB:  PubMed          Journal:  Vet Anaesth Analg        ISSN: 1467-2987            Impact factor:   1.648


  6 in total

1.  Anesthetic Effects of Alfaxalone-Ketamine, Alfaxalone-Ketamine-Dexmedetomidine, and Alfaxalone-Butorphanol-Midazolam Administered Intramuscularly in Five‑striped Palm Squirrels (Funambulus pennantii).

Authors:  David Eshar; Hugues Beaufrère
Journal:  J Am Assoc Lab Anim Sci       Date:  2020-05-29       Impact factor: 1.232

2.  Anesthetic Effects of Intramuscular Alfaxalone-Ketamine in Naked Mole Rats (Heterocephalus glaber).

Authors:  Neta Ambar; David Eshar; Trenton C Shrader; Hugues Beaufrère
Journal:  J Am Assoc Lab Anim Sci       Date:  2020-07-17       Impact factor: 1.232

3.  Effects of a single intravenous bolus injection of alfaxalone on canine splenic volume as determined by computed tomography.

Authors:  Michelle M M Hasiuk; Fernando L Garcia-Pereira; Clifford R Berry; Gary W Ellison
Journal:  Can J Vet Res       Date:  2018-07       Impact factor: 1.310

4.  Anesthetic effect of a mixture of alfaxalone, medetomidine, and butorphanol for inducing surgical anesthesia in ICR, BALB/c, and C57BL/6 mouse strains.

Authors:  Yoriko Tsukamoto; Norihide Yamada; Kenjiro Miyoshi; Kazuto Yamashita; Takeo Ohsugi
Journal:  J Vet Med Sci       Date:  2019-05-10       Impact factor: 1.267

5.  Cardiorespiratory and anesthetic effects produced by the combination of butorphanol, medetomidine and alfaxalone administered intramuscularly in Beagle dogs.

Authors:  Jongsung Lee; Sangil Suh; Ran Choi; Changbaig Hyun
Journal:  J Vet Med Sci       Date:  2015-08-09       Impact factor: 1.267

6.  Pharmacokinetics of intramuscular alfaxalone and its echocardiographic, cardiopulmonary and sedative effects in healthy dogs.

Authors:  Inga-Catalina Cruz-Benedetti; Isabelle Bublot; Thibault Ribas; Isabelle Fourel; Claus Vogl; Claire Dubois; Mathilde Milani; Keila Kazue Ida; Karine Portier
Journal:  PLoS One       Date:  2018-09-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.